https://scholars.lib.ntu.edu.tw/handle/123456789/596358
標題: | Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery | 作者: | Lee T.-Y. CHIN-TARNG LIN Kuo S.-Y. Chang D.-K. Wu H.-C. |
公開日期: | 2007 | 卷: | 67 | 期: | 22 | 起(迄)頁: | 10959-10965 | 來源出版物: | Cancer Research | 摘要: | Antiangiogenesis therapies for the treatment of cancers hold the promise of high efficacy and low toxicity. In vivo phage display was used to identify peptides specifically targeting tumor blood vessels. The peptide SP5-52 recognized tumor neovasculature but not normal blood vessels in severe combined immunodeficiency mice bearing human tumors. Synthetic peptide was shown to inhibit the binding of PC5-52 phage particles to the tumor mass in the competitive inhibition assay. Several selected phage clones displayed the consensus motif, proline-serine-proline, and this motif was crucial for peptide binding to the tumor neovasculature. SP5-52 peptides also bound vascular endothelial growth factor-stimulated human umbilical vein endothelial cells and blood vessels of human lung cancer surgical specimens. Furthermore, this targeting phage was shown to home to tumor tissues from eight different types of human tumor xenografts following in vivo phage display experiments. An SP5-52 peptide-linked liposome carrying doxorubicin enhanced the therapeutic efficacy of the drug, markedly decreased tumor blood vessels, and resulted in higher survival rates of human lung and oral cancer-bearing xenograft mice. The current study indicates that ligand-targeted therapy offers improved therapeutic effects over conventional anticancer drug therapy, and that the peptide SP5-52 specifically targets tumor neovasculature and is a good candidate for targeted drug delivery to solid tumors. ?2007 American Association for Cancer Research. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-36348935200&doi=10.1158%2f0008-5472.CAN-07-2233&partnerID=40&md5=1abb9cff16f255a5e7bd0b79f1851efb https://scholars.lib.ntu.edu.tw/handle/123456789/596358 |
ISSN: | 0008-5472 | DOI: | 10.1158/0008-5472.CAN-07-2233 | SDG/關鍵字: | doxorubicin; liposome; proline; protein sp5 52; serine; synthetic peptide; unclassified drug; vasculotropin; doxorubicin; peptide; peptide library; angiogenesis; animal experiment; animal model; article; bacteriophage; blood vessel; cell homing; controlled study; drug delivery system; drug effect; drug inhibition; human; human cell; in vivo study; lung cancer; mouse; mouth cancer; nonhuman; priority journal; protein binding; protein motif; protein protein interaction; SCID mouse; survival rate; tumor xenograft; umbilical vein; animal; cancer transplantation; chemistry; cytology; disease model; drug delivery system; lung tumor; mouse mutant; mouth tumor; neovascularization (pathology); pathology; tumor cell line; vascular endothelium; Animals; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Drug Delivery Systems; Endothelium, Vascular; Humans; Lung Neoplasms; Mice; Mice, SCID; Mouth Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Peptide Library; Peptides |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。